Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability and safety of Grazax in adults with grass pollen allergy
2009-014522-41Phase 4Completed
- Sponsor
- ALK-Abelló
- Start
- Oct 2009
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of phleum pratense allergen extract in allergic rhinoconjunctivitis (ARC) and grass pollen allergy, sponsored by ALK-Abelló. Primary endpoint: Safety and tolerability of Grazax. Started Oct 2009; status: completed.
02
Drugs
phleum pratense allergen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)grass pollen allergy
Beyond the preview
Go deeper on 2009-014522-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014522-41.